1. Home
  2. CDXS vs MIST Comparison

CDXS vs MIST Comparison

Compare CDXS & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Codexis Inc.

CDXS

Codexis Inc.

HOLD

Current Price

$1.81

Market Cap

141.8M

Sector

Industrials

ML Signal

HOLD

Logo Milestone Pharmaceuticals Inc.

MIST

Milestone Pharmaceuticals Inc.

HOLD

Current Price

$2.66

Market Cap

163.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CDXS
MIST
Founded
2002
2003
Country
United States
Canada
Employees
N/A
N/A
Industry
Major Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
141.8M
163.2M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
CDXS
MIST
Price
$1.81
$2.66
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$6.33
AVG Volume (30 Days)
1.5M
3.4M
Earning Date
11-06-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$52,932,000.00
N/A
Revenue This Year
$15.64
N/A
Revenue Next Year
$5.23
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.52
$0.63
52 Week High
$6.08
$2.77

Technical Indicators

Market Signals
Indicator
CDXS
MIST
Relative Strength Index (RSI) 47.95 70.83
Support Level $1.62 $2.52
Resistance Level $1.79 $2.75
Average True Range (ATR) 0.10 0.19
MACD 0.05 0.03
Stochastic Oscillator 96.88 86.54

Price Performance

Historical Comparison
CDXS
MIST

About CDXS Codexis Inc.

Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.

About MIST Milestone Pharmaceuticals Inc.

Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).

Share on Social Networks: